title: Combination chemotherapy for non small cell lung cancer stage III M0-1 with cisplatin and vinblastine in a divided-dose schedule.
abstract: Twenty-nine patients with advanced non small cell lung cancer (NSCLC) were treated with a combination of high-dose cisplatin and divided-dose vinblastine. In 27 evaluable patients 15% reached partial response and 59% stable disease. Extension of disease, histological type, performance status and weight loss had no relationship to response. Median duration of response was 10.2 months with a median survival time of 15.4 months in responding patients compared with 14 months of stable disease (p:n.s.) and 4.8 months of progressive disease (p less than 0.001). Gastrointestinal, neurological side effects and the development of a severe debilitation syndrome were the most troublesome toxicities of this treatment. The regimen is not generally suitable for treatment of advanced NSCLC.
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D003404:Creatinine / Q000097:blood; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D014747:Vinblastine / Q000008:administration & dosage
chemical_list: D014747:Vinblastine; D003404:Creatinine; D002945:Cisplatin